骨病,如骨质疏松症,会引起破骨细胞过度分化,骨形成减少,导致骨重塑失衡,骨结合不良,可认为是钛种植体的相对禁忌症。多巴胺(DA)可能通过在不同浓度下抑制破骨细胞和促进成骨细胞来解决这个问题。然而,目前的商业植入物不能加载骨活性分子,如 DA。因此,本研究旨在开发一种种植体表面改性方法,以实现 DA 的受控释放并增强钛种植体对骨吸收和骨再生的抵抗力。在球霰石改性的钛表面上成功组装了负载 DA 的藻酸盐-精氨酸-甘氨酸-天冬氨酸 (RGD) (AlgR) 涂层,持续稳定地释放DA。体外研究表明,具有良好生物相容性的材料不仅可以抑制核因子-κB (NFκB) 受体激活剂配体 (RANKL) 诱导的破骨细胞生成,还可以增强人骨髓间充质干细胞 (hBMSCs) 的粘附和成骨分化. 这种双向调节的最佳 DA 负载浓度为 100 μM。有趣的是,与传统的免费给药相比,当从钛涂层中以持续方式释放 DA 时,DA 能更有效地减弱破骨细胞生成,并且藻酸盐-RGD 涂层和 DA 明显表现出极大的协同作用。本研究提供了一种钛种植体表面改性设计,以改善种植体周围的骨重塑。体外研究表明,具有良好生物相容性的材料不仅可以抑制核因子-κB (NFκB) 受体激活剂配体 (RANKL) 诱导的破骨细胞生成,还可以增强人骨髓间充质干细胞 (hBMSCs) 的粘附和成骨分化. 这种双向调节的最佳 DA 负载浓度为 100 μM。有趣的是,与传统的免费给药相比,当从钛涂层中以持续方式释放 DA 时,DA 能更有效地减弱破骨细胞生成,并且藻酸盐-RGD 涂层和 DA 明显表现出极大的协同作用。本研究提供了一种钛种植体表面改性设计,以改善种植体周围的骨重塑。体外研究表明,具有良好生物相容性的材料不仅可以抑制核因子-κB (NFκB) 受体激活剂配体 (RANKL) 诱导的破骨细胞生成,还可以增强人骨髓间充质干细胞 (hBMSCs) 的粘附和成骨分化. 这种双向调节的最佳 DA 负载浓度为 100 μM。有趣的是,与传统的免费给药相比,当从钛涂层中以持续方式释放 DA 时,DA 能更有效地减弱破骨细胞生成,并且藻酸盐-RGD 涂层和 DA 明显表现出极大的协同作用。本研究提供了一种钛种植体表面改性设计,以改善种植体周围的骨重塑。
"点击查看英文标题和摘要"
Controlled release of dopamine coatings on titanium bidirectionally regulate osteoclastic and osteogenic response behaviors
Bone diseases, for example, osteoporosis, cause excessive differentiation of osteoclasts and decreased bone formation, resulting in imbalance of bone remodeling and poor osseointegration, which can be considered a relative contraindication for titanium implants. Dopamine (DA) might provide a solution to this problem by inhibiting osteoclasts and promoting osteoblasts at different concentrations. However, current commercial implants cannot load bone-active molecules, such as DA. Therefore, this study aimed to develop a surface modification method for implants to achieve a controlled release of DA and enhance the resistance of titanium implants to bone resorption and bone regeneration. DA-loaded alginate-arginine-glycine-aspartic acid (RGD) (AlgR) coatings on a vaterite-modified titanium surface were successfully assembled, which continuously and steadily released DA. In vitro studies have shown that materials showing good biocompatibility can not only inhibit receptor activator of nuclear factor-kappa B (NFκB) ligand (RANKL)-induced osteoclastogenesis but also enhance the adhesion and osteogenic differentiation of human bone marrow mesenchymal stem cells (hBMSCs). The optimal DA-loaded concentration of this bidirectional regulation is 100 μM. Interestingly, DA more effectively attenuated osteoclastogenesis when released in a sustained manner from titanium coatings than it did via traditional, free administration, and the alginate-RGD coating and DA clearly exhibited great synergy. This study provides a design of titanium implant surface modification to improve bone remodeling around implants.